Related Experiment Video
Updated: May 27, 2026
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Is prevention the best treatment? CMV after lung transplantation
N Patel1, L D Snyder, A Finlen-Copeland
1Department of Pharmacy Department of Medicine, Duke University, Durham, NC, USA.
Abstract:
Cytomegalovirus (CMV) is the most prevalent opportunistic infection that occurs in lung-transplant recipients. In addition to its direct morbidity, multiple studies have demonstrated that CMV, in particular CMV pneumonia, is associated with an increased risk for chronic graft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttransplant survival. Therefore, prevention of CMV remains an important goal to improve long-term lung-transplant outcomes. Although centers often employed 3 months of prophylaxis in at-risk patients after lung transplantation, a significant proportion of patients still developed infection or disease after the discontinuation of prophylaxis, highlighting the need for more effective approaches to CMV prevention. A number of early single-center reports suggested benefit to extending prophylaxis to longer durations, but concerns regarding cost, late-onset CMV disease, viral resistance and bone marrow toxicity limited enthusiasm for longer durations. However, several recent studies including a multicenter, prospective, randomized, double-blinded clinical trial have demonstrated significant benefits to extending CMV prophylaxis beyond 3 months. Although some areas of controversy remain, the clinical implications of these recent studies suggest that extending prophylaxis with valganciclovir up to 12 months is clearly beneficial for CMV prevention after lung transplantation.
Insights
Extending Cytomegalovirus (CMV) prophylaxis to 12 months after lung transplantation significantly reduces infection and improves long-term outcomes. This approach is more effective than the traditional 3-month regimen for preventing CMV disease in transplant recipients.
Area of Science:
- Transplantation immunology
- Infectious diseases
- Pulmonary medicine
Background:
- Cytomegalovirus (CMV) is a common opportunistic infection post-lung transplant.
- CMV infection, particularly pneumonia, is linked to chronic graft dysfunction (bronchiolitis obliterans syndrome) and reduced survival.
- Current 3-month prophylaxis protocols are insufficient, with many patients developing CMV post-discontinuation.
Purpose of the Study:
- To evaluate the efficacy of extended Cytomegalovirus (CMV) prophylaxis beyond 3 months in lung transplant recipients.
- To determine if longer prophylaxis durations improve long-term outcomes and reduce CMV-related complications.
- To address the need for more effective CMV prevention strategies in this high-risk population.
Main Methods:
- Review of recent studies, including a multicenter, prospective, randomized, double-blinded clinical trial.
- Analysis of data comparing extended CMV prophylaxis durations (up to 12 months) with shorter regimens.
- Assessment of clinical outcomes, including CMV infection/disease incidence and graft function.
Main Results:
- Recent studies demonstrate significant benefits of extending CMV prophylaxis beyond 3 months.
- Extending prophylaxis with valganciclovir up to 12 months is associated with improved CMV prevention.
- This extended duration addresses the limitations of shorter prophylaxis periods.
Conclusions:
- Extending Cytomegalovirus (CMV) prophylaxis to 12 months is clearly beneficial for preventing CMV after lung transplantation.
- Longer prophylaxis durations are necessary to mitigate the risks of CMV infection and chronic graft dysfunction.
- This strategy offers a more effective approach to improving long-term lung transplant outcomes.
More Related Videos
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Related Concept Videos
01:27Cytomegalovirus Disease
01:27Cryptococcal Meningitis
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.